Dendritic cell-derived MYD88 potentiates as a biomarker for immune regulation in hepatocellular carcinoma and may predict a better immunological result
These findings underscore the critical role of MYD88 in DC function, suggesting its potential as a biomarker for immunoregulation in HCC. By shaping the TME, MYD88 not only regulates the immune response in HCC but also influences patient clinical outcomes. Both ex vivo and <i>in vivo</i> experiments further validate that MYD88 impacts DC functionality, contributing to variations in HCC progression.
Authors
- Songjiang He
- Yi Yao (ORCID: https://orcid.org/0000-0003-3110-1720)
- Hengbo Zhu
- Zheming Liu (ORCID: https://orcid.org/0000-0001-5610-6558)
- Qibin Song (ORCID: https://orcid.org/0000-0002-4350-0916)
- Fengxia Zhang (ORCID: https://orcid.org/0000-0002-3925-5495)
- Xue Zhang (ORCID: https://orcid.org/0000-0002-1243-475X)
- Wenting Huang
- Shipeng Zhu
Institutions
- Wuhan University (CN)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.3389/fcell.2025.1554705
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05